Review

anti-mouse pe-trem-1 (174031) (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems anti-mouse pe-trem-1 (174031)

<t>TREM-1</t> is expressed on peripheral myeloid-derived suppressor cells (MDSC) subsets, tumor-infiltrating MDSC, and tumor-associated macrophages in tumor-bearing mice. (A) TREM-1 expression on splenic granulocytic MDSC (PMN-MDSC) and monocytic MDSC (Mo-MDSC) from naïve or tumor-bearing mice 21 days after 4T1 inoculation. (B) TREM-1 levels on tumor-derived Mo-MDSC 0, 7, 15, and 21 days after the 4T1 tumor challenge. * p < 0.05 relative to naïve mice, ** p < 0.0. (C) TREM-1 expression on PMN-MDSC, Mo-MDSC, and tumor-associated macrophages isolated from tumors of tumor-bearing mice 21 days after 4T1 injection. One representative histogram is shown for each population out of more than three independent experiments.

Anti Mouse Pe Trem 1 (174031), supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse pe-trem-1 (174031)/product/R&D Systems
Average 90 stars, based on 1 article reviews

anti-mouse pe-trem-1 (174031) - by Bioz Stars, 2026-06

90/100 stars

Images

1) Product Images from "Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma"

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

Journal: Frontiers in Oncology

doi: 10.3389/fonc.2021.662723

TREM-1 is expressed on peripheral myeloid-derived suppressor cells (MDSC) subsets, tumor-infiltrating MDSC, and tumor-associated macrophages in tumor-bearing mice. (A) TREM-1 expression on splenic granulocytic MDSC (PMN-MDSC) and monocytic MDSC (Mo-MDSC) from naïve or tumor-bearing mice 21 days after 4T1 inoculation. (B) TREM-1 levels on tumor-derived Mo-MDSC 0, 7, 15, and 21 days after the 4T1 tumor challenge. * p < 0.05 relative to naïve mice, ** p < 0.0. (C) TREM-1 expression on PMN-MDSC, Mo-MDSC, and tumor-associated macrophages isolated from tumors of tumor-bearing mice 21 days after 4T1 injection. One representative histogram is shown for each population out of more than three independent experiments.

Figure Legend Snippet: TREM-1 is expressed on peripheral myeloid-derived suppressor cells (MDSC) subsets, tumor-infiltrating MDSC, and tumor-associated macrophages in tumor-bearing mice. (A) TREM-1 expression on splenic granulocytic MDSC (PMN-MDSC) and monocytic MDSC (Mo-MDSC) from naïve or tumor-bearing mice 21 days after 4T1 inoculation. (B) TREM-1 levels on tumor-derived Mo-MDSC 0, 7, 15, and 21 days after the 4T1 tumor challenge. * p < 0.05 relative to naïve mice, ** p < 0.0. (C) TREM-1 expression on PMN-MDSC, Mo-MDSC, and tumor-associated macrophages isolated from tumors of tumor-bearing mice 21 days after 4T1 injection. One representative histogram is shown for each population out of more than three independent experiments.

Techniques Used: Derivative Assay, Expressing, Isolation, Injection

TREM-1 engagement enhances pro-inflammatory cytokine release by myeloid-derived suppressor cells (MDSC) and Trem-1 + MDSC from tumor-bearing mice suppress T cell proliferation. (A) Peripheral myeloid-derived suppressor cells were sorted from spleens of 4T1 tumor-bearing mice, plated onto wells coated with either anti-TREM-1 or rat IgG2A isotype control Ab, and stimulated with lipopolysaccharide. The supernatants were harvested 20 h later, and the TNF levels in the supernatants were measured by ELISA. * p < 0.05. (B) Ly6C + CD11b + (Mo) and (C) Ly6G + CD11b + (PMN) MDSC were sorted from spleens of 4T1 tumor-bearing mice. The cells were cultured at the indicated ratios with splenocytes from naïve BALB/c mice. Con A was added to each well at a final concentration of 2 μg/ml. Tritiated thymidine incorporation was measured during the last 18 h of the 85-h incubation period. * p -value <0.05 relative to no suppressors. Data represents mean ± SEM from triplicates of a representative experiment.

Figure Legend Snippet: TREM-1 engagement enhances pro-inflammatory cytokine release by myeloid-derived suppressor cells (MDSC) and Trem-1 + MDSC from tumor-bearing mice suppress T cell proliferation. (A) Peripheral myeloid-derived suppressor cells were sorted from spleens of 4T1 tumor-bearing mice, plated onto wells coated with either anti-TREM-1 or rat IgG2A isotype control Ab, and stimulated with lipopolysaccharide. The supernatants were harvested 20 h later, and the TNF levels in the supernatants were measured by ELISA. * p < 0.05. (B) Ly6C + CD11b + (Mo) and (C) Ly6G + CD11b + (PMN) MDSC were sorted from spleens of 4T1 tumor-bearing mice. The cells were cultured at the indicated ratios with splenocytes from naïve BALB/c mice. Con A was added to each well at a final concentration of 2 μg/ml. Tritiated thymidine incorporation was measured during the last 18 h of the 85-h incubation period. * p -value <0.05 relative to no suppressors. Data represents mean ± SEM from triplicates of a representative experiment.

Techniques Used: Derivative Assay, Enzyme-linked Immunosorbent Assay, Cell Culture, Concentration Assay, Incubation

TREM-2 is expressed in monocytic MDSC (Mo-MDSC) and tumor-associated macrophages (TAM), and a possible ligand is expressed in TAM. (A) sTREM-2 levels in the plasma of naïve, 4TI-bearing mice or in the wash of 4T1 excised tumors. (B, C) Trem2 expression by qPCR in B6 macrophages, 4T1 cells, splenic MDSC, or TAM as indicated. (B) Relative Trem2 mRNA expression in B6 macrophages compared to 4TI cells demonstrating a neglectable Trem1 expression in tumor cells. (C, D) Relative Trem2 and Trem1 mRNA expression in sorted splenic PMN-MDSC, Mo-MDSC, or TAM sorted from 4T1 tumors removed from mice (see <xref ref-type=

Supplementary Figures S2 – S4 for the gating strategy). Data are normalized to a Trem1 - and Trem2 -expressing macrophage cell line (B6 Line). (E) Single-cell suspensions from 4T1 tumors from tumor-bearing mice were stained with MDSC markers and human (hu) IgG-Fc (gray shaded), TREM-1/hu IgG-Fc (dashed line), or TREM-2/hu IgG-Fc (solid line, no shading), followed by PE-labeled anti-human IgG-Fc. The TREM/hu IgG-Fc expression is shown on gated Gr-1 - CD11b + TAM. " title="... MDSC markers and human (hu) IgG-Fc (gray shaded), TREM-1/hu IgG-Fc (dashed line), or TREM-2/hu IgG-Fc (solid line, ..." property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet: TREM-2 is expressed in monocytic MDSC (Mo-MDSC) and tumor-associated macrophages (TAM), and a possible ligand is expressed in TAM. (A) sTREM-2 levels in the plasma of naïve, 4TI-bearing mice or in the wash of 4T1 excised tumors. (B, C) Trem2 expression by qPCR in B6 macrophages, 4T1 cells, splenic MDSC, or TAM as indicated. (B) Relative Trem2 mRNA expression in B6 macrophages compared to 4TI cells demonstrating a neglectable Trem1 expression in tumor cells. (C, D) Relative Trem2 and Trem1 mRNA expression in sorted splenic PMN-MDSC, Mo-MDSC, or TAM sorted from 4T1 tumors removed from mice (see Supplementary Figures S2 – S4 for the gating strategy). Data are normalized to a Trem1 - and Trem2 -expressing macrophage cell line (B6 Line). (E) Single-cell suspensions from 4T1 tumors from tumor-bearing mice were stained with MDSC markers and human (hu) IgG-Fc (gray shaded), TREM-1/hu IgG-Fc (dashed line), or TREM-2/hu IgG-Fc (solid line, no shading), followed by PE-labeled anti-human IgG-Fc. The TREM/hu IgG-Fc expression is shown on gated Gr-1 - CD11b + TAM.

Techniques Used: Expressing, Staining, Labeling

Expression of TREM in RENCA tumors. (A) Representative FACS plot (left) showing the staining of RENCA-associated CD45 + leukocytes with TREM-1 and F4/80. Data from a quadrant analysis of three individual mice are grafted (right). Staining of the quadrants is noted below the graph. (B) Soluble TREM-1 as determined by ELISA. The mean +/- SEM for five individual mice in each group is plotted. (C) qPCR analysis of Trem2 on RNA isolated from whole RENCA tumors (tumor) at day 22 after implantation. Relative values compared to splenocytes isolated from healthy mice (spleen) and splenocytes isolated from tumor-bearing mice (tumor spleen) are shown. * p < 0.05, **p < 0.01, and ****p < 0.0001.

Figure Legend Snippet: Expression of TREM in RENCA tumors. (A) Representative FACS plot (left) showing the staining of RENCA-associated CD45 + leukocytes with TREM-1 and F4/80. Data from a quadrant analysis of three individual mice are grafted (right). Staining of the quadrants is noted below the graph. (B) Soluble TREM-1 as determined by ELISA. The mean +/- SEM for five individual mice in each group is plotted. (C) qPCR analysis of Trem2 on RNA isolated from whole RENCA tumors (tumor) at day 22 after implantation. Relative values compared to splenocytes isolated from healthy mice (spleen) and splenocytes isolated from tumor-bearing mice (tumor spleen) are shown. * p < 0.05, **p < 0.01, and ****p < 0.0001.

Techniques Used: Expressing, Staining, Enzyme-linked Immunosorbent Assay, Isolation

TREM-1+ myeloid cells infiltrate human renal tumors. (A) Average TREM-1 mean fluorescence intensity on peripheral blood polymorphonuclear neutrophils (PMN) and monocytes (B) from healthy (n = 3) vs. RCC donors (n = 5). (C) CD16 expression on peripheral blood PMN from healthy vs. RCC donors; *pvalue < 0.05.

Figure Legend Snippet: TREM-1+ myeloid cells infiltrate human renal tumors. (A) Average TREM-1 mean fluorescence intensity on peripheral blood polymorphonuclear neutrophils (PMN) and monocytes (B) from healthy (n = 3) vs. RCC donors (n = 5). (C) CD16 expression on peripheral blood PMN from healthy vs. RCC donors; *pvalue < 0.05.

Techniques Used: Fluorescence, Expressing

sTREM-1 levels are increased in the plasma of patients with renal cell carcinoma. (A) Serum from healthy donors ( n = 10) or patients with either localized ( n = 5) or metastatic ( n = 9) renal cell carcinoma (RCC) was tested for soluble TREM-1 (sTREM-1) levels by ELISA. (B) sTREM-1 levels between stage I (localized) and stage IV (metastatic) RCC patients demonstrating a trend towards higher levels with worsening stage. (C) sTREM-1 levels in RCC patients from the Fox Chase Cancer Center ( n = 63) and healthy controls ( n = 20). (D) Percent of CD45+ blood leukocytes expressing TREM-1 in RCC patients and healthy controls. (E) Soluble TREM-1 levels are plotted vs . the percentages of blood leukocytes expressing TREM-1 in RCC (left) and healthy controls (right). The r values and p -values of the correlation analysis are shown. (F) Fluorescence intensity (geometric mean) of TREM-1 staining of RCC patients is plotted against the sTREM-1 values for those same patients. The r values and p -values of the correlation analysis are shown.

Figure Legend Snippet: sTREM-1 levels are increased in the plasma of patients with renal cell carcinoma. (A) Serum from healthy donors ( n = 10) or patients with either localized ( n = 5) or metastatic ( n = 9) renal cell carcinoma (RCC) was tested for soluble TREM-1 (sTREM-1) levels by ELISA. (B) sTREM-1 levels between stage I (localized) and stage IV (metastatic) RCC patients demonstrating a trend towards higher levels with worsening stage. (C) sTREM-1 levels in RCC patients from the Fox Chase Cancer Center ( n = 63) and healthy controls ( n = 20). (D) Percent of CD45+ blood leukocytes expressing TREM-1 in RCC patients and healthy controls. (E) Soluble TREM-1 levels are plotted vs . the percentages of blood leukocytes expressing TREM-1 in RCC (left) and healthy controls (right). The r values and p -values of the correlation analysis are shown. (F) Fluorescence intensity (geometric mean) of TREM-1 staining of RCC patients is plotted against the sTREM-1 values for those same patients. The r values and p -values of the correlation analysis are shown.

Techniques Used: Enzyme-linked Immunosorbent Assay, Expressing, Fluorescence, Staining

The Cancer Genome Atlas analysis shows that TREM-1 expression is increased in renal cell carcinoma (RCC) patients and correlates with a poor outcome. (A) Box plots showing Trem1 mRNA expression for normal (72) and stages I–IV ( n = 267, 57, 123, and 84, respectively) RCC patients, with the medians represented as blue bars in a box, and each case is shown as a pink dot. (B) Trem1 expression levels in 531 RCC tumor samples from TCGA were stratified into tertiles of Trem1 expression levels (low = 3rd quartile, high = 3rd tertile, and NC = intertertile range. (C) Kaplan–Meier overall survival curves according to this strata and (D) for higher-stage diseases (stage III and above).

Figure Legend Snippet: The Cancer Genome Atlas analysis shows that TREM-1 expression is increased in renal cell carcinoma (RCC) patients and correlates with a poor outcome. (A) Box plots showing Trem1 mRNA expression for normal (72) and stages I–IV ( n = 267, 57, 123, and 84, respectively) RCC patients, with the medians represented as blue bars in a box, and each case is shown as a pink dot. (B) Trem1 expression levels in 531 RCC tumor samples from TCGA were stratified into tertiles of Trem1 expression levels (low = 3rd quartile, high = 3rd tertile, and NC = intertertile range. (C) Kaplan–Meier overall survival curves according to this strata and (D) for higher-stage diseases (stage III and above).

Techniques Used: Expressing

Image Search Results

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: TREM-1 is expressed on peripheral myeloid-derived suppressor cells (MDSC) subsets, tumor-infiltrating MDSC, and tumor-associated macrophages in tumor-bearing mice. (A) TREM-1 expression on splenic granulocytic MDSC (PMN-MDSC) and monocytic MDSC (Mo-MDSC) from naïve or tumor-bearing mice 21 days after 4T1 inoculation. (B) TREM-1 levels on tumor-derived Mo-MDSC 0, 7, 15, and 21 days after the 4T1 tumor challenge. * p < 0.05 relative to naïve mice, ** p < 0.0. (C) TREM-1 expression on PMN-MDSC, Mo-MDSC, and tumor-associated macrophages isolated from tumors of tumor-bearing mice 21 days after 4T1 injection. One representative histogram is shown for each population out of more than three independent experiments.

Article Snippet: The anti-mouse PE-TREM-1 (174031) and PE-Rat IgG2A (54447) isotype control as well as recombinant mouse TREM-1 Fc chimera, TREM-2 Fc chimera, and human IgG1 Fc were purchased from R&D Systems.

Techniques: Derivative Assay, Expressing, Isolation, Injection

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: TREM-1 engagement enhances pro-inflammatory cytokine release by myeloid-derived suppressor cells (MDSC) and Trem-1 + MDSC from tumor-bearing mice suppress T cell proliferation. (A) Peripheral myeloid-derived suppressor cells were sorted from spleens of 4T1 tumor-bearing mice, plated onto wells coated with either anti-TREM-1 or rat IgG2A isotype control Ab, and stimulated with lipopolysaccharide. The supernatants were harvested 20 h later, and the TNF levels in the supernatants were measured by ELISA. * p < 0.05. (B) Ly6C + CD11b + (Mo) and (C) Ly6G + CD11b + (PMN) MDSC were sorted from spleens of 4T1 tumor-bearing mice. The cells were cultured at the indicated ratios with splenocytes from naïve BALB/c mice. Con A was added to each well at a final concentration of 2 μg/ml. Tritiated thymidine incorporation was measured during the last 18 h of the 85-h incubation period. * p -value <0.05 relative to no suppressors. Data represents mean ± SEM from triplicates of a representative experiment.

Techniques: Derivative Assay, Enzyme-linked Immunosorbent Assay, Cell Culture, Concentration Assay, Incubation

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: TREM-2 is expressed in monocytic MDSC (Mo-MDSC) and tumor-associated macrophages (TAM), and a possible ligand is expressed in TAM. (A) sTREM-2 levels in the plasma of naïve, 4TI-bearing mice or in the wash of 4T1 excised tumors. (B, C) Trem2 expression by qPCR in B6 macrophages, 4T1 cells, splenic MDSC, or TAM as indicated. (B) Relative Trem2 mRNA expression in B6 macrophages compared to 4TI cells demonstrating a neglectable Trem1 expression in tumor cells. (C, D) Relative Trem2 and Trem1 mRNA expression in sorted splenic PMN-MDSC, Mo-MDSC, or TAM sorted from 4T1 tumors removed from mice (see Supplementary Figures S2 – S4 for the gating strategy). Data are normalized to a Trem1 - and Trem2 -expressing macrophage cell line (B6 Line). (E) Single-cell suspensions from 4T1 tumors from tumor-bearing mice were stained with MDSC markers and human (hu) IgG-Fc (gray shaded), TREM-1/hu IgG-Fc (dashed line), or TREM-2/hu IgG-Fc (solid line, no shading), followed by PE-labeled anti-human IgG-Fc. The TREM/hu IgG-Fc expression is shown on gated Gr-1 - CD11b + TAM.

Techniques: Expressing, Staining, Labeling

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: Expression of TREM in RENCA tumors. (A) Representative FACS plot (left) showing the staining of RENCA-associated CD45 + leukocytes with TREM-1 and F4/80. Data from a quadrant analysis of three individual mice are grafted (right). Staining of the quadrants is noted below the graph. (B) Soluble TREM-1 as determined by ELISA. The mean +/- SEM for five individual mice in each group is plotted. (C) qPCR analysis of Trem2 on RNA isolated from whole RENCA tumors (tumor) at day 22 after implantation. Relative values compared to splenocytes isolated from healthy mice (spleen) and splenocytes isolated from tumor-bearing mice (tumor spleen) are shown. * p < 0.05, **p < 0.01, and ****p < 0.0001.

Techniques: Expressing, Staining, Enzyme-linked Immunosorbent Assay, Isolation

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: TREM-1+ myeloid cells infiltrate human renal tumors. (A) Average TREM-1 mean fluorescence intensity on peripheral blood polymorphonuclear neutrophils (PMN) and monocytes (B) from healthy (n = 3) vs. RCC donors (n = 5). (C) CD16 expression on peripheral blood PMN from healthy vs. RCC donors; *pvalue < 0.05.

Techniques: Fluorescence, Expressing

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: sTREM-1 levels are increased in the plasma of patients with renal cell carcinoma. (A) Serum from healthy donors ( n = 10) or patients with either localized ( n = 5) or metastatic ( n = 9) renal cell carcinoma (RCC) was tested for soluble TREM-1 (sTREM-1) levels by ELISA. (B) sTREM-1 levels between stage I (localized) and stage IV (metastatic) RCC patients demonstrating a trend towards higher levels with worsening stage. (C) sTREM-1 levels in RCC patients from the Fox Chase Cancer Center ( n = 63) and healthy controls ( n = 20). (D) Percent of CD45+ blood leukocytes expressing TREM-1 in RCC patients and healthy controls. (E) Soluble TREM-1 levels are plotted vs . the percentages of blood leukocytes expressing TREM-1 in RCC (left) and healthy controls (right). The r values and p -values of the correlation analysis are shown. (F) Fluorescence intensity (geometric mean) of TREM-1 staining of RCC patients is plotted against the sTREM-1 values for those same patients. The r values and p -values of the correlation analysis are shown.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Fluorescence, Staining

Journal: Frontiers in Oncology

Article Title: Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma

doi: 10.3389/fonc.2021.662723

Figure Lengend Snippet: The Cancer Genome Atlas analysis shows that TREM-1 expression is increased in renal cell carcinoma (RCC) patients and correlates with a poor outcome. (A) Box plots showing Trem1 mRNA expression for normal (72) and stages I–IV ( n = 267, 57, 123, and 84, respectively) RCC patients, with the medians represented as blue bars in a box, and each case is shown as a pink dot. (B) Trem1 expression levels in 531 RCC tumor samples from TCGA were stratified into tertiles of Trem1 expression levels (low = 3rd quartile, high = 3rd tertile, and NC = intertertile range. (C) Kaplan–Meier overall survival curves according to this strata and (D) for higher-stage diseases (stage III and above).

Techniques: Expressing

Journal: Cell

Article Title: SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis

doi: 10.1016/j.cell.2021.11.033

Figure Lengend Snippet:

Article Snippet: TREM1-PE , Miltenyi Biotec , Cat# 130-101-033, RRID: AB_2657706.

Techniques: Immunohistochemistry, Plasmid Preparation, Recombinant, Staining, Lysis, Protease Inhibitor, Mass Spectrometry, Sequencing, Modification, Bicinchoninic Acid Protein Assay, Enzyme-linked Immunosorbent Assay, Software

sTLT-1 blocks TREM-1/TREM-1 ligand interactions. (A) Surface plasmon resonance assessment of neutrophils’ supernatants during a time course stimulation with or without LPS for the release of the TREM-1 ligand. (B) Competition assay of TREM-1 ligand (derived from neutrophils stimulated with LPS for 30 min) binding to a rsTREM-1-coated sensorship with increasing concentrations of LR17 (green circles) or LR17 scrambled (black triangles). (C) Flow cytometry analysis of FITC-labeled LR17 (5 μg/ml) binding to resting (upper panel) or thrombin-activated (5 Ul/ml) human platelets (lower panel) is reversed by coincubation with unlabeled LR17, sTLT-1, or LP17, a TREM-1-derived peptide. (D) Neutrophil ROS production after a 2-h stimulation with platelets or platelets/LPS. (E) Trem-1 mRNA and TREM-1 expression in native and Trem-1-silenced monocytes at baseline and upon 24-h LPS stimulation (left), TNF-α concentrations produced by control (electroporated cells without siRNA), or Trem-1-silenced human monocytes stimulated by LPS or a TREM-1 agonist (mAb) (right). Data are representative of at least five different experiments. *p < 0.05, **p < 0.01, ***p < 0.001, LR17 versus LPS and/or anti-TREM-1 mAb.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis

doi: 10.4049/jimmunol.1102674

Figure Lengend Snippet: sTLT-1 blocks TREM-1/TREM-1 ligand interactions. (A) Surface plasmon resonance assessment of neutrophils’ supernatants during a time course stimulation with or without LPS for the release of the TREM-1 ligand. (B) Competition assay of TREM-1 ligand (derived from neutrophils stimulated with LPS for 30 min) binding to a rsTREM-1-coated sensorship with increasing concentrations of LR17 (green circles) or LR17 scrambled (black triangles). (C) Flow cytometry analysis of FITC-labeled LR17 (5 μg/ml) binding to resting (upper panel) or thrombin-activated (5 Ul/ml) human platelets (lower panel) is reversed by coincubation with unlabeled LR17, sTLT-1, or LP17, a TREM-1-derived peptide. (D) Neutrophil ROS production after a 2-h stimulation with platelets or platelets/LPS. (E) Trem-1 mRNA and TREM-1 expression in native and Trem-1-silenced monocytes at baseline and upon 24-h LPS stimulation (left), TNF-α concentrations produced by control (electroporated cells without siRNA), or Trem-1-silenced human monocytes stimulated by LPS or a TREM-1 agonist (mAb) (right). Data are representative of at least five different experiments. *p < 0.05, **p < 0.01, ***p < 0.001, LR17 versus LPS and/or anti-TREM-1 mAb.

Article Snippet: Cells were incubated with soluble rFITC-labeled TLT-1 peptides, FITC-labeled LP17 (or corresponding FITC-labeled scrambled peptides), PE-labeled anti-TREM-1 mAb (R&D Systems), CD62P-FITC, CD66b-PE, CD45-PE, and CD14-FITC (all from Beckman Coulter).

Techniques: SPR Assay, Competitive Binding Assay, Derivative Assay, Binding Assay, Flow Cytometry, Labeling, Expressing, Produced

LR17 modulates the TREM-1 pathway. (A–E) Isolated human neutrophils were stimulated with 100 ng/ml LPS and/or 5 μg/ml αTREM-1, with 10–20 μg/ml LR17 or LR17 scrambled. (A and B) Western blot of lysates of neutrophils treated for 1, 3, 10, 30, and 60 min, analyzed with Ab to phospho (p)-p38, p38, p-ERK1/2, and ERK1/2. (C) Immunoblot of MALT-1 after immunoprecipitation with anti-BCL10 mAb of lysates of neutrophils stimulated for 20 min. (D) ELISA of nuclear p50 and p65 NF-κB subunits of neutrophils treated for 2 h. (E) TNF-α mRNA levels in neutrophils stimulated for 6 h. (F) ELISA quantification of TNF-α production after 6 and 24 h of stimulation. (G) FACS quantification of neutrophil ROS production. Data are representative of at least four different experiments. Results are mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, LR17 versus corresponding LPS and/or anti-TREM-1 mAb.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis

doi: 10.4049/jimmunol.1102674

Figure Lengend Snippet: LR17 modulates the TREM-1 pathway. (A–E) Isolated human neutrophils were stimulated with 100 ng/ml LPS and/or 5 μg/ml αTREM-1, with 10–20 μg/ml LR17 or LR17 scrambled. (A and B) Western blot of lysates of neutrophils treated for 1, 3, 10, 30, and 60 min, analyzed with Ab to phospho (p)-p38, p38, p-ERK1/2, and ERK1/2. (C) Immunoblot of MALT-1 after immunoprecipitation with anti-BCL10 mAb of lysates of neutrophils stimulated for 20 min. (D) ELISA of nuclear p50 and p65 NF-κB subunits of neutrophils treated for 2 h. (E) TNF-α mRNA levels in neutrophils stimulated for 6 h. (F) ELISA quantification of TNF-α production after 6 and 24 h of stimulation. (G) FACS quantification of neutrophil ROS production. Data are representative of at least four different experiments. Results are mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, LR17 versus corresponding LPS and/or anti-TREM-1 mAb.

Techniques: Isolation, Western Blot, Immunoprecipitation, Enzyme-linked Immunosorbent Assay

Elevated levels of plasma TREM-1 ligand in patients diagnosed with sepsis and correlation with severity. (A) Patients admitted into the intensive care unit were evaluated for the presence of plasma TREM-1 ligand by surface plasmon resonance according to the presence of a sepsis or not. Markers represent individual patients. Horizontal lines represent the median. The p values represent results from Mann-Whitney U test. Correlation between plasma TREM-1 ligand concentration and severity of the disease assessed by the SOFA score (B). Rs value was calculated via the Spearman test. (C) Plasma concentration of TREM-1 ligand according to the outcome.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Soluble Trem-like Transcript-1 Regulates Leukocyte Activation and Controls Microbial Sepsis

doi: 10.4049/jimmunol.1102674

Figure Lengend Snippet: Elevated levels of plasma TREM-1 ligand in patients diagnosed with sepsis and correlation with severity. (A) Patients admitted into the intensive care unit were evaluated for the presence of plasma TREM-1 ligand by surface plasmon resonance according to the presence of a sepsis or not. Markers represent individual patients. Horizontal lines represent the median. The p values represent results from Mann-Whitney U test. Correlation between plasma TREM-1 ligand concentration and severity of the disease assessed by the SOFA score (B). Rs value was calculated via the Spearman test. (C) Plasma concentration of TREM-1 ligand according to the outcome.

Techniques: SPR Assay, MANN-WHITNEY, Concentration Assay

Review

Structured Review

Images

1) Product Images from "Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma"

Similar Products

Image Search Results